POLYMED stock news on Anadi Algo News

Tuesday, March 31, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|1 matching stories

POLYMED Share Price, Latest News & Sentiment

Latest AI-analyzed news for POLYMED, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

POLYMED News Today

Emerging stock coverage

The healthcare disposable products segment is a consistently growing market, driven by increasing medical facilities and healthcare expenditure. Companies with strong export capabilities benefit from global demand.

Coverage
1
recent stories
Sources
1
distinct publishers
Bias Split
1 bullish / 0 bearish
0 neutral stories
Window
1d
recent coverage span
Saved Quote Snapshot

Poly Medicure Limited

Last Updated
31 Mar 2026
Price
Rs 1,191.9
-3.11%
52W Range
Rs 1,182 - Rs 2,937.6
exchange snapshot
PE / VWAP
PE 35.38
VWAP Rs 1,203.46
Trend Read
bearish
Bearish stack · EMA 5 < 9 < 21 < 50
Business Context
Industry: Medical Equipment & Supplies
Sector Trail: NIFTY 500
Listing Date: 2011-12-07
Market Structure
F&O Eligible: No
Indices: NIFTY 500, NIFTY MIDSMALL HEALTHCARE, NIFTY MIDSMALLCAP 400
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 30 Sept 2024

Consolidated results
What This Quarter Says

This is the first public financial report for POLYMED. The company reported sales of ₹420.02 crore and a profit of ₹86.7 crore. This information helps you understand how much money the company is making and keeping.

Revenue
Rs 420.02 cr
up 4.4% vs previous filing
Profit
Rs 86.7 cr
down 0.6% vs previous filing
EPS / Finance Cost
EPS 9.01
Finance cost Rs 3.34 cr
Filing Context
Filed 29 Oct 2024, 2:48 am
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 420.02 cr, up 4.4% vs previous filing.
  • Profit this quarter: Rs 86.7 cr, down 0.6% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 9.01.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

Top Themes

Related Stocks

Peer names will show up here once more related-stock mentions appear in coverage.

POLYMED FAQ

Why is POLYMED in the news right now?

POLYMED has appeared across 1 recent stories from 1 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is POLYMED coverage bullish or bearish right now?

POLYMED coverage is currently leaning bullish, with 1 bullish, 0 bearish, and 0 neutral analyzed stories in the recent window.

Which themes are moving with POLYMED?

Recent POLYMED coverage is clustering around auto. Related names showing up alongside POLYMED include the wider peer basket.

How should I use this POLYMED news page?

Use this page as a coverage hub for POLYMED: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use POLYMED coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Look for long-term investment opportunities in Poly Medicure, considering its strong fundamentals and growth trajectory. Monitor quarterly results for continued performance.|Quick check: POLYMED bearish bias (-6.0% 1d), MARUTI bearish bias (oversold).